HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China

BMJ Open

Volumn 4, Issue 10, 2014, Pages

  Leng, Xuebing ^a   Liang, Shujia ^b   Ma, Yanling ^c   Dong, Yonghui ^d   Kan, Wei ^a   Goan, Daniel ^e   Hsi, Jenny H ^a   Liao, Lingjie ^a   Wang, Jing ^a   He, Cui ^a   Zhang, Heng ^a   Xing, Hui ^a   Ruan, Yuhua ^a   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c YUNNAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention   (China)

^e UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RILPIVIRINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE; VIRUS RNA;

ADULT; AGRICULTURAL WORKER; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; CHINESE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG TREATMENT FAILURE; DRUG USE; EDUCATION; ETHNIC GROUP; ETHNICITY; FEMALE; HIGH SCHOOL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PREVALENCE; TREATMENT DURATION; VIROLOGY; VIRUS LOAD; VIRUS MUTATION; BLOOD; COMPLICATION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; SUBSTANCE ABUSE; TREATMENT FAILURE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHINA; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84908090181     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005886     Document Type: Article

References (33)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Patel D, Desai M, Shah AN, et al. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clin Res 2013;4:215-20.
3. Zhang F, Dou Z, Ma Y, et al. Five year outcomes of the China national free antiretroviral treatment program. Ann Intern Med 2009;151:241-51.
4. Sanguansittianant S, Nooroon N, Phaengchomduan P, et al. Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010. J Clin Lab Anal 2013;27:346-53.
5. UNAIDS Global report: UNAIDS report on the global AIDS epidemic 2012. UNAIDS.
6. 2011 Report on the estimation of HIV epidemic in China. Beijing: Ministry of Health, PRC, UNAIDS, World Health Organization, 2011.
7. Zhang L, Chow EP, Jing J, et al. HIV prevalence in China: integration of surveillance data and a systematic review. Lancet Infect Dis 2013;13:955-63.
8. Chinese Center for Disease Control and Prevention: Analysis of HIV/STD epidemic in 2013. Beijing, China.
9. Wang J, He C, Hsi JH, et al. Virological outcomes and drug resistance in Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment, 2011-2012. PLoS ONE 2014;9: e88305.
10. Xing H, Ruan Y, Li J, et al. HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients. PLoS ONE 2013;8:e54917.
11. Zhong P, Pan Q, Ning Z, et al. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 2007;23:847-56.
12. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006;42:1608-18.
13. Wang X, Yang L, Li H, et al. Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. Curr HIV Res 2011;9:103-11.
14. Ruan Y, Xing H, Wang X, et al. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites. Trop Med Int Health 2010;15:1357-63.
15. Wang QX, Wang X, Chen B, et al. Drug resistance and associated factors on HIV in Liangshan prefecture, Sichuan province. Zhonghua Liu Xing Bing Xue Za Zhi 2011;32:1082-6.
16. Li H, Zhong M, Guo M, et al. Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan province, China. PLoS ONE 2013;8: e72630.
17. Wisaksana R, Indrati AK, Fibriani A, et al. Response to first-line antiretroviral treatment among human immunodeficiency virus-infected patients with and without a history of injecting drug use in Indonesia. Addiction 2010;105:1055-61.
18. Zaccarelli M, Barracchini A, De Longis P, et al. Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and Nevirapine. AIDS Patient Care STDS 2002;16:67-73.
19. Knobel H, Guelar A, Carmona A, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS 2001;15:193-9.
20. Waldrop-Valverde D, Valverde E. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDS 2005;19:326-34.
21. Tucker JS, Burnarn MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003;114:573-80.
22. Carrieri MP, Chesney MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med 2003;10:1-14.
23. Nolan S, Milloy MJ, Zhang R, et al. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care 2011;23:980-7.
24. Simoni JM, Amico KR, Pearson CR, et al. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep 2008;10:515-21.
25. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis 2004;38 (Suppl 5):S376-387.
26. Clarke S, Delamere S, McCullough L, et al. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med 2003;4:33-7.
27. Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010;105:907-13.
28. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence evidence from the MANIF2000 cohort study. Addiction 2008;103:1828-36.
29. Li HP, Liu W, Liu HX, et al. Study on the antiviral therapy program among people with human immunodeficiency virus in Guangxi Zhuang Authority. Zhonghua Liu Xing Bing Xue Za Zhi 2007;28:338-42.
30. Yao ST, Duan S, Xiang LF, et al. Survival analysis on 3103 HIV/AIDS patients receiving antiretroviral treatment in Dehong prefecture, Yunnan province. Zhonghua Liu Xing Bing Xue Za Zhi 2010;31:1215-18.
31. Yao S, Yang J, Zhou L, et al. Study on HIV viral load in plasma and drug resistance among AIDS patients receiving antiretroviral treatment in Dehong prefecture,Yunnan province. Zhonghua Liu Xing Bing Xue Za Zhi 2014;35:411-16.
32. Jiang H, Cao X, Wang C, et al. Study on the adherence and related determinants among HIV-positive clients under methadone maintenance treatment in Dali, Yunnan province from 2005 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi 2014;35:255-8.
33. Jiang H, Han Y, Du J, et al. Factors associated with one year retention to methadone maintenance treatment program among patients with heroin dependence in China. Subst Abuse Treat Prev Policy 2014;9:11.